Format

Send to

Choose Destination
J Clin Pathol. 2015 Apr;68(4):309-13. doi: 10.1136/jclinpath-2014-202521. Epub 2015 Jan 8.

Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma.

Author information

1
Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK CRUK Cancer Research Institute, University of Cambridge, Cambridge, UK.
2
Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
3
Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
4
School of Clinical Medicine, University of Cambridge, Cambridge, UK.
5
Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Abstract

BACKGROUND:

Endothelin-1 (ET-1) acting through endothelin A and B receptors (ETAR and ETBR) has been implicated in the development of cancer. The endothelin axis has not previously been characterised in human pancreatic adenocarcinoma (PAC).

METHODS:

Expression of ET-1, ETAR, ETBR, vascular endothelial growth factor and microvessel density (MVD) was determined by immunohistochemistry in 45 surgically resected human PACs and 15 non-cancer human pancreas samples.

RESULTS:

PAC had the highest staining intensity for ET-1 and ETBR: 38% PAC samples scored 2+ or more compared with 7% non-cancer sample in ET-1; 58% PAC samples scored 2+ compared with 0% non-cancer samples in ETBR. MVD was significantly lower in PAC compared with non-cancer tissue (p<0.0001).

CONCLUSIONS:

PAC was characterised by greater expression of ET-1 and ETBR compared with normal pancreas.

KEYWORDS:

ANGIOGENESIS; IMMUNOHISTOCHEMISTRY; PANCREATIC CANCER

PMID:
25572612
DOI:
10.1136/jclinpath-2014-202521
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center